kabutan

CanBas Co.,Ltd.(4575) Summary

4575
TSE Growth
CanBas Co.,Ltd.
691
JPY
+2
(+0.29%)
Apr 28, 3:30 pm JST
4.34
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
668.1
Apr 28, 11:38 pm JST
Summary Chart Historical News Financial Result
PER
PBR
5.81
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
689 JPY 4.32 USD
Previous Close Apr 27
689 JPY 4.32 USD
High Apr 28, 9:50 am
703 JPY 4.41 USD
Low Apr 28, 9:00 am
688 JPY 4.31 USD
Volume
104,400
Trading Value
0.07B JPY 0.45M USD
VWAP
693.45 JPY 4.36 USD
Minimum Trading Value
69,100 JPY 434 USD
Market Cap
0.01T JPY 0.09B USD
Number of Trades
292
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
1,168
1-Year High Aug 21, 2025
19,409
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 1,160,300
Apr 17, 2026 0 1,137,200
Apr 10, 2026 0 1,130,400
Apr 3, 2026 0 1,150,800
Mar 27, 2026 0 1,178,800
Company Profile
CanBas Co., Ltd. is a drug discovery venture specializing in anticancer drug development. Its primary source of income is research and development support funds. The company is actively seeking partnership opportunities.
Sector
Pharmaceuticals
CanBas Co., Ltd. is a drug discovery venture focusing on basic research, early clinical development, and late-stage clinical development of anticancer drugs. Leveraging its unique drug discovery approach, the company has a development pipeline consisting of multiple drug candidate compounds. CanBas utilizes external specialized institutions and a scientific advisory board, aiming for synergy by combining in-house development with strategic partnerships with pharmaceutical companies. The company's lead compound, CBP501, is currently undergoing Phase 2 clinical trials in combination with immune checkpoint inhibitor antibodies. CBS9106 has been licensed to a U.S. company and is progressing through clinical development. In addition to these, CanBas is conducting exploratory research on multiple novel candidate compounds. The company's immediate priorities are accelerating the development of CBP501 and maximizing its chances of success, while continuing basic research to deepen understanding of existing pipelines and generate next-generation pipelines. Continuous fundraising through direct financing is also positioned as one of the company's challenges and strategies to support these efforts.